RNAi nanoparticles in the service of personalized medicine
The understanding of cancer molecular origins and the different intracellular signaling pathways that are perturbed in the various types of malignancies have laid the foundation to realize why patients react diversely to therapy. For example, in colon cancer, an efficient treatment of EGF-receptor blockade with monoclonal antibody was found not to benefit patients with tumors positive for the K-ras mutation [1] . This slowly but steadily brought a shift from a 'one size fits all' therapy approach to a more personalized attitude, in which each patient is treated according to their tumor-specific genetic defects. To support this new approach, a substantial effort is invested in developing a new class of molecular diagnostic tools identifying patients' tumor-personal gene-expression signatures, as well as mutation profiles.
RNA interference (RNAi) is a is a ubiquitous, highly specific, endogenous mechanism of gene silencing that can be activated by incorporating small interfering (si)RNAs into the cell cytoplasm to reduce gene-expression level in a sequence-specific manner. siRNA represents a drug platform, owing to its sequence-specific gene silencing that enables the use of different sequences to reduce distinct genes while keeping the chemical similarity of synthetic 19-21 nucleotide RNA duplexes. In addition, siRNAs can reduce gene expression from the mutated allele whilst keeping the normal one active [2] , therefore, siRNAs are extremely suitable as a drug platform in personalized cancer therapy. However, major obstacles concerning systemic delivery and intracellular off-target effects, as well as immune response, hindered the desired therapeutic goal, bringing uncertainty to its realization. Owing to the poor cellular uptake of naked siRNA and rapid serum RNase clearance, systemic nanocarriers have been developed. The most widely used vehicles are based on positively charged reagents, which encapsulate or complex with the negatively charged nucleic acid. Electrostatic interactions between the carriers and the cell membrane enable intracellular entrance, typically by endocytosis, which requires siRNA release from the endosome to the cytoplasm. Still, accumulating evidence indicates a response of the innate immune system for such particles, leading to toxicity associated with extreme cytokine release. The siRNA entry into the endosome where Toll-like receptor (TLR)7/8 are present probably activates the immune response through the NF-kB pathway by upregulating expression of IFN-a and proinflammatory cytokines. Using a broadbased siRNA screening strategy, it was demonstrated that TLR7/8 immunogenicity is determined mainly by siRNA sequence motifs and thermodynamic properties of the duplexes [3] . However, chemical modifications of the siRNA duplexes, such as 2´-O-methyl uridines, are recognized with high affinity by TLR7/8, but do not induce downstream signaling and can be used to completely avoid the immune effects [4] [5] [6] . siRNA can also be recognized by TLR3, which is located in intracellular compartments, such as the endosome [7] , or on the surface of certain cell types, such as blood endothelial cells. Although it was thought that TLR3 initiates signals in response to virus-derived dsRNA with a minimal length of 40-50 bp [8] , Kleinman et al. showed in endothelial cells that TLR3 is activated by 21 nucleotide siRNA [9] . The TLR3 pathway is functional in different types of tumors and its activation shows various and even opposing effects. Mainly, it was found to induce a type-I interferon response as well as inflammatory cytokine and chemokine production. In addition to TLR-based systems, mammalian cells have evolved a number of non-TLR mechanisms induced by dsRNA-binding protein kinase or retinoic acid-inducible gene 1 proteins that are reviewed elsewhere [10, 11] . Most published work concerning the innate immune response of siRNA disregards the offtarget effect of using carriers to deliver siRNA. In cell culture models, the carrier is used for Editorial Kedmi & Peer siRNA internalization to the cell cytoplasm, while in animal models the carrier is responsible for systemic delivery, coping with greater challenges besides internalization, such as rapid RNA clearance and targeting the carrier to a particular cell type in a specific tissue. Recent evidence indicates that cationic lipids, which have been extensively used as carriers, activate various cellular cascades, including the activation of inflammatory TLR4 signaling by diC14-amidine liposomes [12] , increased expression of dendritic cell costimulatory molecules, CD80 and CD86 [13] , and upregulation of CCL2, -3 and -4 chemokine genes caused by treatment with DOTAP, a cationic lipid [14] (for a detailed review see [15] ). These indications necessitate a revisit of previous conclusions regarding siRNA triggering an immune response, owing to the use of such cationic carriers. Increasing our knowledge on the exact influence of different carriers on various tumors may lead to a wise exploitation of transporters in personalized cancer therapy. Divergent side effects caused by carriers can, in some tumors, promote tumor aggressiveness, while in others they might reduce malignancy and actually contribute to the therapeutic outcome. Chronic inflammation has long been identified to be associated with cancer. Ex vivo TLR4 triggering by lipopolysaccharides in human head and neck squamous cell carcinoma supports cancer progression by promoting tumor cell proliferation and inducing tumor cell resistance to drugmediated apoptosis [16, 17] . However, there are indications that cationic liposome side effects might support cancer therapy. For example, certain cationic lipids elevate intracellular calcium, which is known to function in the regulation of cell death [18, 19] and, hence, might be used to eradicate tumor cells [20] . Induction of the CCL3 gene by cationic carriers might also be used to promote therapy in certain tumors. Nakashima et al. demonstrated reduced tumori genicities in vivo in adenocarcinoma cells transfected with CCL3 [21] . Others have demonstrated that CCL3 plays a role in multiple myeloma progression as a downstream target of FGF receptor 3 [22] . This reflects the complexity and variability in using cationic carriers in cancer therapy. Therefore, a detailed intensive study should be conducted to examine the effect of various cationic carriers on different categories of tumors in distinct individuals.
An additional strategy for dealing with a carrier's off-target effect is to engineer nontoxic immune-privilege carriers. We have recently constructed liposomes made from neutral phospholipids and coated with hyaluronan, a naturally accruing glycosaminoglycan, in order to prevent an immune response. The hyaluronan coating endows these carriers with longcirculating properties and stabilizes the carriers in vivo. The hyaluronan coating was also used as a scaffold for monoclonal antibody binding to direct the carriers to specific leukocyte cell type [23] . Distinct classes of tumors and the variations between individuals facilitate the need for personalized medicine. In fact, a higher level of complexity relies on tumor subpopulation composition. Cells in the tumor differ in their function and contribution, as well as in their gene expression, mutation profile and cell-surface markers. Such subpopulations may include cancer stem cells [24] , metastatic cells, as well as cells from the microenvironment contributing to tumor progression, such as macrophages [25] . The future vision for siRNA-based personalized medicine is a specific cell-type therapy, in which a range of carriers encapsulated with different siRNA sequences will tackle the tumor sub populations by exploiting the different cell surface markers to release a distinct cargo best suited for those specific cells in a particular patient. No writing assistance was utilized in the production of this manuscript.
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